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Corneal diseases and blindness can result from deficiency in limbal stem cells, and autologous transplanta-
tion is often the only therapeutic option. Two recent studies inNature have provided insights into regulation of
limbal stem cell function and corneal regeneration and present new opportunities for clinical interventions in
eye diseases.A clear cornea is essential for visual acuity
and depends on stromal avascularity and
epithelial integrity. Corneal renewal and
repair are mediated by stem cells of the
limbus, the narrow zone between the
cornea and the bulbar conjunctiva. Stem
cells comprise a minority of clonogenic
cells in the limbus, while non-self-renew-
ing transient amplifying progenitors with
limited proliferative potential represent
over 95% of cells with clonogenic activity
(Pellegrini et al., 1999). These cells further
differentiate and give rise to suprabasal,
terminally differentiated keratinocytes,
which form the outer barrier of the epithe-
lium. Ocular burns may destroy the
limbus, causing limbal stem cell defi-
ciency (LSCD). In such cases, the cornea
acquires an epithelium through the inva-
sion of bulbar conjunctival cells. This pro-
cess leads to neovascularization, chronic
inflammation, and stromal scarring, re-
sulting in corneal opacity and loss of
vision. The only way to prevent conjunc-
tival invasion is to restore the limbus by
transplantation of either autologous lim-
bal grafts (Kenyon and Tseng, 1989) or
limbal cultures (Pellegrini et al., 1997).
Autologous stem cells are required for
permanent regeneration of a functional
corneal epithelium, because allogenic
cells do not engraft or persist and might
act only as temporary biological medica-
tion. While some molecular regulators of
limbal stem cell function were proven to
be instrumental for the clinical success
of limbal cultures (Rama et al., 2010),
defining new factors is extremely valuable
for the selection and control of stem cells
and the improvement of cell therapy stra-
tegies for treating eye disease. Two
recent papers inNature nowprovide addi-
tional insights into the control of limbalstem cell behavior during homeostasis
and in injury (Ksander et al., 2014; Ouyang
et al., 2014).
Ksander and colleagues report that
ATP-binding cassette subfamily B mem-
ber 5 (ABCB5) is a regulator of mamma-
lian limbal stem cell behavior and is
required for corneal development and
repair. ABCB5 was expressed in the
majority of label-retaining cells of the
basal layer of the mouse limbus. In
human eyes, ABCB5+ cells were located
in the basal layer of the limbus and coex-
pressed DNp63a—a known regulator of
regenerative potential in epithelial stem
cells (Senoo et al., 2007), including
human limbal stem (Pellegrini et al.,
2001)—which was not expressed in
ABCB5 cells. The frequency of ABCB5+
cells was observed to be lower in patients
with LSCD, and limbal epithelial cultures
prepared from syngeneic mice or human
biopsies were able to permanently regen-
erate a corneal epithelium when trans-
planted into immunodeficient mice with
induced LSCD. Strikingly, long-term
corneal restoration was attained only
when grafts contained ABCB5+ cells or
were prepared from prospectively iso-
lated ABCB5+ cells.
Ksander and colleagues found that
ABCB5 knockout animals exhibit some
corneal abnormalities, including overall
decreased cellularity accompanied by
increased proliferation and apoptosis.
The observation that ABCB5 knockout lit-
termates develop a corneal epithelium
that retains the capability of repairing cen-
tral corneal injuries, however, suggests
that corneal abnormalities arising from
ABCB5 deficiency could be ascribed to
the antiapoptotic role of the protein and
that ABCB5 may play a role in regulatingCell Stem Cell 1homeostasis of the limbal/corneal epithe-
lium. The compensatory proliferation of
nonapoptotic, basal keratinocytes could
explain the observations regarding prolif-
eration and cellularity in ABCB5 knockout
mice, as well as the decreased number of
label-retaining cells. The corneal opacifi-
cation observed in extreme experimental
conditions, such as the transplantation
of cultured grafts made from ABCB5
cells, might reflect the loss of such a
compensatory mechanism due to the
transplantation of a pure population of
ABCB5 cells.
Ouyang and colleagues (Ouyang et al.,
2014) report that WNT7A controls corneal
epithelium differentiation through PAX6, a
pleiotropic transcription factor guiding
eye morphogenesis. The authors show
that WNT7A and PAX6 are coexpressed
in vivo and in vitro by limbal/corneal
epithelial cells, but not by epidermal kera-
tinocytes. Expression of WNT7A/PAX6
and the corneal-specific K3/K12 keratins
was absent in areas of corneal squa-
mous metaplasia, a phenotype typically
observed in corneal diseases such as
inflammatory keratopathy. Short-hairpin-
RNA-mediated downregulation of WNT7a
or PAX6 decreased the expression of
K3/K12 and induced the expression of
the skin-specific K1/K10 keratins, sug-
gesting that knockdown of these factors
converts corneal epithelium into an
epidermal-like state. While the ABCB5
knockout mice generated by Ksander
display highly reduced expression of
PAX6, expression of K1/K10 was not
investigated. Of note, Ouyang et al.
demonstrate that transgenic expression
of PAX6 in human epidermal cells induced
a corneal cell phenotype, indicated by the
expression of K3/K12. Strikingly, grafts5, August 7, 2014 ª2014 Elsevier Inc. 121
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epidermal cells transplanted onto a rabbit
model of LSCD were able to repopulate
the limbus and regenerate a bona fide
corneal epithelium, even after repeated
central corneal damage. This interesting
observation awaits confirmation in long-
lasting, self-renewing human epidermal
stem cells. Themaintenance of the human
corneal phenotype in the presence of
stromal cells should be also confirmed
because stromal cells may influence
epithelial cell behavior.
Nevertheless, these data are consistent
with the notion that both in transgenic
mouse models and in human diseases,
i.e., aniridia, absence or disruptive muta-
tions of PAX6 causes severe alteration of
the corneal epithelium and might have
important clinical implications. Indeed,
transplantation of autologous cultures
of limbal cells is a safe and effective
treatment for chemical-burn-dependent
corneal destruction associated with
LSCD. The essential requirement of this
cell therapy approach is the need for an
adequate number of stem cells (Rama
et al., 2010), in this case measured as
holoclones (Barrandon and Green, 1987;
Pellegrini et al., 1999) expressing high
levels of DNp63a. This approach, how-122 Cell Stem Cell 15, August 7, 2014 ª2014ever, cannot be applied to blindness re-
sulting from total bilateral LSCD, because
by definition these patients lack autolo-
gous limbal stem cells that are necessary
to prepare the grafts. The possibility of
generating a bona fide functional, self-
renewing corneal epithelium by genetic
reprogramming of easily accessible autol-
ogous squamous stem cells with a critical
transcription factor could represent an
important step forward toward new clin-
ical approaches for eye diseases. These
findings could guide development of
novel treatments for blindness due to
complete bilateral destruction of the
corneal epithelium and total LSCD
through the use of genetically modified
epidermal stem cells (Mavilio et al.,
2006), once safety and proper regulation
of transgene expression are ensured.
Future studies will help to determine
whether this approach could be clinically
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